Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Expectations By $1.64 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its quarterly earnings data on Friday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.87) by $1.64, Zacks reports.

Indaptus Therapeutics Trading Down 9.1%

Shares of INDP traded down $0.16 during midday trading on Friday, reaching $1.59. The stock had a trading volume of 82,975 shares, compared to its average volume of 53,759. The company has a market capitalization of $3.56 million, a price-to-earnings ratio of -0.10 and a beta of 1.37. The company’s 50-day moving average is $2.15 and its 200 day moving average is $2.32. Indaptus Therapeutics has a 12-month low of $1.51 and a 12-month high of $19.91.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.